FDA decision expected within six months of acceptance
Pivotal phase 3 clinical trial of treosulfan met primary endpoint and key secondary endpoints
Treosulfan NDA Resubmitted to FDA
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/amazon%20holiday%20delivery%20boxes%20by%20Cineberg%20via%20iStock.jpg)
/NVIDIA%20Corp%20logo%20on%20phone%20and%20AI%20chip-by%20Below%20the%20Sky%20via%20Shutterstock.jpg)
/Semiconductor%20Chip%20by%20Gorodenkoff%20via%20Shutterstock.jpg)
/Lululemon%20Athletica%20inc_%20leggings%20by-%20Sorbis%20via%20Shutterstock.jpg)
/Palo%20Alto%20Networks%20Inc%20HQ%20sign-by%20Tada%20Images%20via%20Shutterstock.jpg)